glp-1 and gip receptors The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Polyagonists Enable Increasingly Effective Treatment

Singh G, Eng J, and Raufman JP

Flavor: Strawberry

& Song, B.-J

Weekly exposure (57 days/week) Weekly Exposure From the 1:1 Pre-blended Vial Daily blend dose 0.5 mg/day Weekly total blend 2.53.5 mg Weekly BPC-157 1.251.75 mg Weekly TB-500 1.251.75 mg Daily blend dose 1.0 mg/day Weekly total blend 5.07.0 mg Weekly BPC-157 2.53.5 mg Weekly TB-500 2.53.5 mg Daily blend dose 1.5 mg/day Weekly total blend 7.510.5 mg Weekly BPC-157 3.755.25 mg Weekly TB-500 3.755.25 mg Daily blend dose 2.0 mg/day Weekly total blend 10.014.0 mg Weekly BPC-157 5.07.0 mg Weekly TB-500 5.07.0 mg Use this to compare a blend schedule against the separate-vial weekly totals in the next tab